Fig. 1

There was a significant positive correlation between FUBP1 and NB malignancy and a significant negative correlation with survival rate independent of N-Myc. (a) Immunohistochemistry staining of N-Myc and division into two categories: N-Myc high expression (n = 24) and N-Myc low expression (n = 41) according to the histochemistry score (H-score) of neuroblastoma TMA tissue (NB: n = 65). (b) Immunohistochemistry staining of FUBP1 and division into two categories: FUBP1 high expression (n = 48) and FUBP1 low expression (n = 17) according to the H-score on neuroblastoma TMA tissue (NB: n = 65). (c) Statistical analysis of the H-Score of FUBP1 and N-Myc in NB samples. (d) Statistical analysis of the H-Score of FUBP1 and N-Myc in the INSS NB stage 1–4.(e) Survival analysis of 44 NB pathologic subtype patients divided into four categories: high FUBP1 and low N-Myc expression (n = 19); low FUBP1 and high N-Myc expression (n = 5); high FUBP1 and high N-Myc expression (n = 12); low FUBP1 and low N-Myc expression (n = 8). High expression was considered a H-Score ≥ 5. (f) Statistical analysis of the H-Score of FUBP1 in NB TMA, which consists of 123 neuroblastoma tumour tissue samples (NB: n = 65; GNB: n = 31; GN: n = 27). (g) Western blot analysis of FUBP1 expression in frozen peripheral neuroblastic tumour (pNT) tissue samples (5 NB, 5 GNB). β-Actin served as a loading control. (h) Survival of NB patients with high expression of FUBP1 (H-Score ≥ 5; n = 33) versus those with low expression of FUBP1 (H-Score < 5; n = 37). (i) Statistical analysis of the ki67-positive ratio in high and low expression of FUBP1 in NB tissue from clinical data. Error bars represent the standard deviation (SD); one asterisk, p < 0.05; asterisks, p < 0.001